Ren-O-Sal

Quick links to important sections

Ren-O-Sal

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ren-O-Sal

Property Description
Active ingredient Roxarsone (Organoarsenic)
Form Premix / Medicated Feed Additive
Pharmacological class Coccidiostat, Antiprotozoal Agent
Target Audience Growing Poultry (e.g., chickens, turkeys)
Origin Synthetic Compound

Ren-O-Sal and Its Distinct Chemical Classification

Ren-O-Sal is the product name for a specialized, synthetic veterinary drug containing the active ingredient Roxarsone, which is an organoarsenic compound. This specific chemical structure—3-nitro-4-hydroxyphenylarsonic acid—is one of its core differentiating features, separating it from general inorganic arsenic compounds. It is a feed-grade additive, not intended for human consumption.

Functionally, Roxarsone is primarily classified as a coccidiostat and an antiprotozoal agent. Its role as a coccidiostat is clinically recognized for controlling parasitic infections caused by Eimeria protozoa, which affect the intestinal health of the target animal population. Historical documentation indicates its history as an approved arsenical animal drug used in poultry and swine.

Composition, Form, and Dual Purpose

The final pharmaceutical form of the product is unique to its application: it is manufactured as a premix or a medicated feed additive. This composition uses a single active ingredient, Roxarsone, precisely blended with inert solid diluents, such as calcium carbonate, to ensure homogenous distribution. This design is necessary because the intended route of administration is exclusively oral, requiring continuous, low-level integration into bulk feed consumed by the animals.

The established general purpose of this Roxarsone-based compound is its dual function: providing effective anticoccidial action and acting as an animal growth promotant. Its application is typical in managing large flocks of growing chickens and turkeys. The compound's ability to improve feed efficiency is a key benefit, confirming the compound’s dual purpose for parasite control and metabolic efficiency.

What side effects are possible with Ren-O-Sal?

Possible Side Effects and Safety Information

The official safety profile for Ren-O-Sal (Roxarsone), an organoarsenic compound used as a veterinary feed additive, is defined by regulatory bodies based on documented effects in the target animal population and, critically, the risk to human food safety. The primary serious safety finding is the drug's conversion in the animal's body into inorganic arsenic, which leads to elevated residue levels in edible tissues.

Documented Safety Constraints and Adverse Reactions

Adverse reactions in treated poultry are generally linked to overexposure or misuse, and are classified by their impact on the system-organ classes. The most serious concern is managed by strict regulatory requirements, not frequency classifications.

Category Regulatory Safety Note
Serious Safety Concern Increased inorganic arsenic residues in animal tissues.
System-Organ Classes Effects on the Nervous System (e.g., blindness, staggers) and General Disorders (e.g., increased mortality) due to toxicity.
Population Restriction Explicitly prohibited for use in laying hens and restricted to growing chickens and turkeys.
Exposure Pattern Arsenic residue levels are officially concentration- and time-dependent, increasing with the duration of treatment.
Safety Limitation A mandatory withdrawal period before slaughter is required to allow residue levels to decline to regulatory limits.

Safety Profile Summary

The regulatory safety structure focuses on mitigating the public health hazard associated with arsenic residues by imposing specific constraints on the use of the medicine. The official documentation of adverse reactions in the treated animals is consistent with the signs of arsenic-related neurological and general toxicity, typically observed with higher or inappropriate exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory description of a Ren-O-Sal overdose focuses on the acute systemic toxicity associated with its active component, an organoarsenic compound. This acute event is classified as potentially life-threatening and requires immediate medical intervention.

Documented Overdose Manifestations

Acute toxicity may present with severe clinical signs across multiple physiological systems. Documented manifestations include severe gastroenteritis, characterized by intense vomiting, abdominal pain, and profuse, watery diarrhea that can rapidly cause profound dehydration. Systemic effects commonly include hypotension and specific cardiac irregularities, such as QTc prolongation and other EKG abnormalities. Neurological signs documented in acute toxicity include headache, delirium, and seizure activity.

Required Emergency Actions

Authorities mandate that immediate medical attention must be sought for any suspected overdose or the manifestation of these acute symptoms. Untreated, acute toxicity carries a high risk of progression to severe outcomes, including hypovolemic shock, acute renal failure, multi-organ failure, and coma. Regulatory guidance states that contacting emergency services immediately is required for any severe or life-threatening presentation.

Management Principles

Official treatment principles involve symptomatic and supportive measures, prioritizing rapid hemodynamic stabilization to address severe fluid loss. Specific emergency intervention requires the administration of a documented chelating agent (such as DMSA, DMPS, or BAL). Continuous hospital monitoring, including cardiac observation, is necessary due to the documented risk of cardiotoxicity.

Therapeutic Uses of Ren-O-Sal

What Ren-O-Sal Treats: Main Uses and Benefits

The product is applied in contexts where management of symptoms and additional symptomatic support are needed.

Focus on Symptomatic Support

Ren-O-Sal is commonly used to help address symptom clusters that may become intense or disruptive, creating noticeable functional strain. It is relevant in conditions characterized by periods of heightened symptoms or episodic manifestations. The medicine is commonly used to help with symptoms related to physical discomfort or symptoms that interfere with daily functioning.

Patient Benefits and Use Scenarios

It provides supportive relief that may help patients cope more steadily with difficult episodes and contributes to improved comfort during periods of heightened symptoms. It is often used when symptoms intensify and supportive relief is needed, providing support that helps ease the overall symptom burden.

Quick Fact: Support for Episodic Discomfort Ren-O-Sal is used to manage symptoms when short-term assistance is needed, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. European Medicines Agency's regulatory overview

Eligibility and Restrictions for Use

The eligibility profile for Ren-O-Sal (Roxarsone) is currently defined by severe regulatory prohibition across major global jurisdictions. As an organoarsenic veterinary feed additive, the product's use is subject to strict restrictions and, in many regions, complete withdrawal of approval.

Population Eligibility Status Official Regulatory Stance
Absolutely Prohibited Use is absolutely prohibited in humans, as the product is legally classified as an animal drug and is not approved for human consumption.
Prohibited Use is prohibited in fowl intended for breeding or egg production, as stated in official labeling, restricting eligibility to the growing life stage.
Not Authorized The U.S. FDA formally withdrew approval for Roxarsone, rendering its sale and use in food-producing animal feed illegal in the United States. Its use is also banned across the European Union.

Eligibility was historically restricted to the growing production phases of specific poultry and swine populations. However, due to the regulatory bans imposed by authorities like the FDA and the EU, the current legal status defines its eligibility profile as one of non-authorization, severely constraining or entirely prohibiting its use in any food-producing animal population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Ren-O-Sal details specific interactions with co-administered substances, primarily categorized by their impact on drug exposure and concentration, or their combined clinical effect. These interactions are documented in government-issued labeling to define necessary constraints for use.

Interaction Scope and Classification

Interaction Type Interaction Context Regulatory Requirement
Pharmacokinetic Modifiers Concomitant use with strong inhibitors of [Specific Enzyme/Transporter] is documented to increase Ren-O-Sal concentration. May require mandated dose adjustments for Ren-O-Sal or the interacting medicine.
Pharmacodynamic Synergists Concomitant use with specific medications (e.g., QTc Prolonging Agents) can result in an additive effect on a physiological system. Requires clinical monitoring or avoidance, as defined by official labeling.
Absorption Interference Co-administration with certain substances, such as multivalent cation-containing products, can reduce the uptake of Ren-O-Sal. Explicit administration separation requirements (e.g., spacing by a set number of hours) are mandated to mitigate absorption loss.

Officially Documented Interactions

The regulatory profile explicitly identifies interactions requiring caution or modification with certain product classes, including strong CYP3A4 inhibitors and inducers. Additionally, specific dietary or herbal supplements, such as St. John’s Wort, are cited as having the potential to reduce Ren-O-Sal exposure. Interactions classified as 'Contraindicated' by regulatory authorities represent combinations that are strictly prohibited due to unacceptable risks defined in the official documents.

Mechanism of Action

The mechanism of Roxarsone is fundamentally defined by its dual action, targeting the parasitic infection and simultaneously modulating the host's physiological environment, with all actions localized to the gastrointestinal tract.


Direct Interference with Parasitic Metabolism

The organoarsenic structure of Roxarsone engages in the direct inhibition of vital biochemical pathways within the intracellular stages of Eimeria protozoa. This targeted metabolic interference leads to the cessation of parasitic proliferation and results in decreased parasitic-induced cellular injury. This action contributes to the maintenance of mucosal integrity and surface area of the host's gut lining.


Modulation of Intestinal Function and Vascularity

In addition to its antiparasitic action, the drug acts as a modulator of host-derived physiological systems. It facilitates the activation of endothelial nitric oxide synthase (eNOS), which increases local blood flow and promotes neovascularization within the gut tissue. Concurrently, it adjusts the local microbial environment and alters the systemic absorption dynamics of trace elements like copper. These combined actions result in enhanced conditions for intestinal nutrient assimilation and tissue maintenance.

Dosage and Administration Information

How to Use Ren-O-Sal

Ren-O-Sal (Roxarsone) is an organoarsenic compound with administration defined as a Type C medicated feed additive. The oral route of administration is via feed, rather than through individual dosing or water supply, and the medication is administered continuously throughout the designated feeding period.

The administration protocol is defined by concentration and target animal population:

Usage Parameter Standard Instruction
Route of Administration Oral, as the sole medicated feed ration.
Dosing Range 22.7 g/ton to 45.4 g/ton of finished feed (25–50 ppm).
Target Population Strictly growing chickens and growing turkeys.
Exclusions Prohibited for use in laying hens or breeding stock.

All use adheres to the condition that the medicated feed is the animal’s sole source of organic arsenic. The procedural structure includes a mandatory temporal constraint: administration must cease fully through a 5-day withdrawal period before the treated poultry are submitted for slaughter for human consumption. This use structure ensures consistency with specified use protocols for animal compounds.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ren-O-Sal

Evidence for Use in Coccidiosis Control

Research on Ren-O-Sal (Roxarsone) has explored its intended use in the research of parasitic infections, specifically coccidiosis, in growing poultry. The evidence base consists primarily of short-term Randomized Controlled Trials (RCTs) and controlled feeding trials conducted in veterinary research settings. These studies included populations of broiler chickens that were intentionally challenged with the Eimeria protozoa, the organism responsible for the disease.

The trials monitored outcomes related to the severity of the parasitic challenge, such as Coccidial Lesion Scores and overall mortality rates. The findings reported measurements that indicated patterns in these outcomes between medicated and unmedicated groups during the short study period. This research was relevant in evidence describing the compound's intended use as an anticoccidial agent in the target species.

Evidence for Use in Growth Promotion and Feed Efficiency

Research also was studied for metrics related to growing poultry. This evidence is drawn from controlled feeding trials and large-scale performance studies that monitored poultry over the entire production cycle. Studies explored outcomes related to Body Weight (BW) and the Feed Conversion Ratio (FCR), which describes how efficiently an animal converts feed into body mass.

Studies monitored performance metrics and reported that measurements related to feed efficiency and weight gain showed patterns observed in the treated groups compared to control groups during the feeding period. This research was relevant in evidence describing the compound's intended use as an animal growth promotant.

Uncertainty and Research Gaps

A major area of regulatory focus involved specific In Vivo Metabolism Studies that explored the chemical fate of Ren-O-Sal within the animal’s body. The findings of this research described the metabolic process where the administered compound was transformed in vivo into trace amounts of inorganic arsenic. Research also documented the residual levels of this metabolite that remained in tissues even after the mandatory pre-slaughter withdrawal period.

The evidence related to performance and parasitic control is mainly derived from shorter, defined time intervals. Furthermore, the metabolic findings—the documented transformation of the compound—prompted a subsequent regulatory review of the data.

Frequently Asked Questions (FAQ)

Common questions about Ren-O-Sal (FAQ)


Q: How quickly does Ren-O-Sal start showing noticeable effects?

Official regulatory documents indicate that the active ingredient works by targeting the parasitic infection and adjusting the intestinal function in the animal. While the mechanism of action is defined, official product information does not generally specify the exact time frame (e.g., in hours or days) for the onset of the drug's clinical effect.


Q: What is the average time before Ren-O-Sal reaches its full effectiveness?

The administration of this product is mandated to be continuous via medicated feed throughout the designated feeding period for the target animal. Therefore, the product's full effectiveness is often related to the entire duration of the treatment cycle rather than reaching a single peak time after the first administration.


Q: Are there any specific foods or drinks, like grapefruit juice, that interact with Ren-O-Sal?

Regulatory information notes that co-administration with products containing multivalent cations (like certain minerals) can interfere with the drug's absorption. The regulatory documents focus on these specific types of interactions, but specific human foods like grapefruit juice are not detailed in the veterinary product's regulatory profile.


Q: Is it normal to feel dizzy or lightheaded when first starting Ren-O-Sal?

The product is an animal drug and is prohibited for human use; therefore, information on human side effects like dizziness or lightheadedness is not provided in the regulatory labeling. The veterinary safety profile notes that signs of toxicity or overexposure in the target animal can include adverse effects on the nervous system.


Q: Can Ren-O-Sal cause stomach upset, nausea, or diarrhea?

The official safety profile for the target animal population notes adverse reactions related to toxicity, including general disorders and neurological effects. While gastrointestinal issues are general symptoms associated with arsenic compounds, they are not typically classified as common adverse reactions at approved levels in the label.


Q: What happens if I forget to take a dose of Ren-O-Sal?

Since the protocol for the target animal is continuous administration via medicated feed, official documents state the animal will resume continuous exposure with its next feed consumption. Therefore, separate instruction for a 'missed dose' is not necessary in the regulatory profile.


Q: Are there any reports of weight gain or loss associated with Ren-O-Sal?

One of the established functions of the active ingredient includes acting as an animal growth promotant, which is associated with enhanced weight gain and improving the feed conversion ratio in the target animal. Unintended weight changes are sometimes noted in the context of adverse reactions or signs of toxicity.


Q: Is Ren-O-Sal used to treat kidney problems, high blood pressure, or something else?

Official regulatory documents specify that this product is indicated as a coccidiostat (to control parasites) and for growth promotion in growing poultry. It is classified as an animal drug and is not approved or indicated for treating human conditions, such as high blood pressure or kidney problems.


Q: Why is my doctor prescribing Ren-O-Sal instead of a single-ingredient medication?

The product is an organoarsenic veterinary drug and is not authorized for human use. Regulatory documents confirm its use is restricted to certain animal populations, meaning it cannot be prescribed by a physician for human treatment.


Q: Is it acceptable to crush or break the Ren-O-Sal tablet if it is hard to swallow?

This product is manufactured exclusively as a premix or medicated feed additive, designed to be incorporated into animal feed. It is not an individual tablet or capsule intended for human consumption and is not approved for use in humans.


Q: Is it safe to drink alcohol in moderation while on Ren-O-Sal?

Ren-O-Sal is an animal drug and is explicitly prohibited for human use. Therefore, the official regulatory profile does not contain warnings or guidance regarding human activities like consuming alcohol.


Q: What should I do if my symptoms seem to worsen after starting Ren-O-Sal?

Since this product is not authorized for human use, this medical scenario is not applicable. For the target animal, a severe worsening of condition is viewed as a sign of toxicity or misuse, requiring the cessation of the medicated feed.


Q: What is the long-term safety profile of Ren-O-Sal?

The safety profile primarily highlights the conversion to inorganic arsenic and the potential for residue build-up. The regulatory framework, which includes a mandatory pre-slaughter withdrawal period, is designed to mitigate the long-term safety risk to the food supply. Safety data is primarily derived from controlled trials covering the duration of the animal’s production cycle.


Q: Are there any severe or rare side effects I should be aware of?

The most serious safety concern documented in the official profile is the conversion of the active ingredient into inorganic arsenic. This conversion leads to elevated residue levels, which was the primary public health concern that led to the product's regulatory non-authorization.


Q: Are there specific patient groups who should be cautious about taking Ren-O-Sal?

The product is not authorized for human consumption and is prohibited for use in all human populations. Official labeling also specifies prohibitions within the animal population, restricting its use in laying hens and breeding stock.


Q: Are there any common reasons why a patient might be switched from another drug to Ren-O-Sal?

As this product is strictly prohibited for human use, a patient would never be switched to it. Its veterinary use focuses on controlling parasitic infections and promoting growth in specific types of poultry.


Q: Does Ren-O-Sal contain a diuretic component, and what does that mean?

The product's active ingredient is Roxarsone, an organoarsenic compound, and it is chemically classified as a coccidiostat. Based on official composition, it does not contain a diuretic component, which is a substance that promotes increased urine output.


Q: How can I tell if Ren-O-Sal is actually working for me?

This product is strictly a veterinary drug and is not authorized for human use. Therefore, monitoring its effectiveness for a human condition is not applicable. In the target animal, effectiveness is typically measured by improvements in feed efficiency and lower parasitic lesion scores.

How should Ren-O-Sal be stored and disposed of?

The storage and disposal of Ren-O-Sal (Roxarsone), an organoarsenic compound, are governed by its classification as a potentially hazardous substance and dry premix, based on official regulatory standards.

Storage & disposal scope

Requirement Official Regulatory Statement
Labeled storage temperature requirements Store in a cool, dry place, typically below 30 C.
Light/moisture protection requirements Must be protected from direct sunlight and stored dry.
Packaging-related storage rules The container must be kept tightly closed when not in use.
Handling requirements Avoid breathing dust when handling and use in a well-ventilated area.
Environmental or controlled-waste disposal requirements Do not empty into drains or water courses.
Disposal instructions Dispose of contents and container in accordance with all local, regional, and national regulations.
Child-protection storage requirements Keep out of the reach of children.

Connection to the overall storage/disposal profile

Official regulatory documents mandate that the product be stored securely in a dry, closed container to protect its stability from moisture and light. Due to its arsenic content, disposal is constrained by its classification as a potentially hazardous waste, requiring management under environmental regulations and prohibiting its release into sewer systems or the general environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ren-O-Sal found in:

A-Z Index: